Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting

Singapore Medical Journal

Volumn 53, Issue 8, 2012, Pages 526-531

  Hasan, Syed Shahzad ^a   Lim, Kim Nai ^b   Anwar, Mudassir ^b   Sathvik, Belagodu Sridha ^b   Ahmadi, Keivan ^c   Yuan, Adelyn Wei Li ^d   Kamarunnesa, Mokhtar Ahmad ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c MONASH UNIVERSITY MALAYSIA   (Malaysia)

^d Hospital Serdang   (Malaysia)

Author keywords

Drug interaction; Identification; Intensive care; Management; Pharmacist

Indexed keywords

CEFTRIAXONE; DOBUTAMINE; DOPAMINE; ERYTHROMYCIN; GLUCONATE CALCIUM; MAGNESIUM SULFATE; MIDAZOLAM; MORPHINE; NORADRENALIN; RANITIDINE; TRAMADOL;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COMORBIDITY; CONTROLLED STUDY; DRUG DRUG INTERACTION; DRUG MONITORING; DRUG USE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GENDER; HUMAN; INFANT; INTENSIVE CARE UNIT; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHARMACIST; PHYSICAL EXAMINATION; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHARMACISTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84870041599     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mitchell G.W, Stanaszek W.F, Nichols N.B. Documenting drug-drug interactions in ambulatory patients. Am J Hosp Pharm 1979; 36:653-657.
2. Jankel C.A, Speedie S.M. Detecting drug interactions: a review of the literature. DICP 1990; 24:982-989.
3. Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996; 44:944-948.
4. Fijn R, Van den Bemt P.M, Chow M, et al. Hospital prescribing errors: epidemiological assessment of predictors. Br J Clin Pharmacol 2002; 53:326-331.
5. Johnson J.A, Bootman J.L. Drug-related morbidity and mortality. A cost-ofillness model. Arch Intern Med 1995; 155:1949-1956.
6. Thomas A, Routledge P.A. Drug interactions in clinical practice. Focus Pharmacovigilance Bull. 2003:1-7.
7. Classen D.C, Pestotnik S.L, Evans R.S, Lloyd J.F, Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277:301-306.
8. Levy M, Kewitz H, Altwein W, Hillebrand J, Eliakim M. Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17:25-31.
9. Cruciol-Souza J.M, Thomson J.C. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006; 9:427-33.
10. Heininger-Rothbucher D, Bischinger S, Ulmer H, et al. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 2001; 49:283-288.
11. Grönroos P.E, Irjala K.M, Huupponen R.K, et al. A medication database-tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 1997; 53:13-7.
12. Wiltink EH. Medication control in hospitals: a practical approach to the problem of drug-drug interactions. Pharm World Sci 1998; 20:173-177.
13. Coelho P.V, Brum C.A. Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Coronel Fabriciano, Minas Gerais State, Brazil. Cad Saude Publica 2009; 25:2229-2236.
14. Goldberg R.M, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14:447-1450.
15. Cadieux R.J. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 1989; 86:179-186.
16. Sloan R.W. Drug interactions. Am Fam Physician 1983; 27:229-238.
17. Astrand B, Astrand E, Antonov K, Petersson G. Detection of potential drug interactions-a model for a national pharmacy register. Eur J Clin Pharmacol 2006; 62:749-756.
18. Tulner L.R, Frankfort S.V, Gijsen G.J, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25:343-355.
19. Costa A.J. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991; 8:234-236.
20. May J.R, DiPiro J.T, Sisley J.F. Drug interactions in surgical patients. Am J Surg 1987; 153:327-335.
21. Morera T, Gervasini G, Carrillo J.A, Benitez J. Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. Ann Pharmacother 2004; 38:1301-1306.
22. Buurma H, De Smet P.A, Egberts A.C. Clinical risk management in Dutch community pharmacies. Drug Saf 2006; 29:723-732.
23. Glassman P.A, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40:1161-1171.
24. Weideman R.A, Bernstein I.H, McKinney W.P. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999; 56:1524-1529.
25. Malone D.C, Hutchins D.S, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62:1983-1991.
26. Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ 1999; 161:1266-1267.
27. Bates D.W, Cullen D.J, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274:29-34.
28. Thomson Reuters (Healthcare) Inc. MICROMEDEX Gateway. [online]. Available at: www.thomsonhc.com/home/dispatch. Accessed May 28, 2012.
29. Hansten PD, Horn JR, eds. Drug Interactions Analysis and Management. St. Louis: Facts and Comparisons, 2009.
30. Lexi-Comp OnlineTM, Pediatric Lexi-Drugs OnlineTM, Hudson, Ohio: Lexi-Comp, Inc.; 2009.[online]. Avaliable at: www.lexi.com/institutions/ products/online/. Accessed July 27, 2009.
31. Hutson W.R, Roehrkasse R.L, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989; 96:11-7.
32. Seymour R.M, Routledge P.A. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12:485-494.
33. Glintborg B, Andersen S.E, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 2005; 61:675-681.
34. Cusack B.J. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2:274-302.
35. Becker M.L, Visser L.E, van Gelder T, Hofman A, Stricker B.H. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging 2008; 25:145-152.
36. Ford D.R Jr, Rivers N.P, Wood G.C. A computerized detection system for potentially significant adverse drug-drug interactions. J Am Pharm Assoc 1977; 17:354-357.
37. Schneitman-McIntire O, Farnen T.A, Gordon N, Chan J, Toy W.A. Medication misadventures resulting in emergency department visits at and HMO medical center. Am J Health Syst Pharm 1996; 53:1416-1422.
38. Egger S.S, Drewe J, Schlienger R.G. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58:773-778.
39. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64:1840-1843.
40. Quinn DI, Day RO. Drug interactions of clinical importance. An updated guide. Drug Saf 1995; 12:393-452.
41. Leape L.L, Cullen D.J, Clapp M.D, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282:267-270.